Algert Global LLC Boosts Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Algert Global LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 45.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,342 shares of the company’s stock after buying an additional 3,832 shares during the quarter. Algert Global LLC’s holdings in CRISPR Therapeutics were worth $667,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CRSP. Capital International Investors boosted its position in CRISPR Therapeutics by 27.8% in the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares in the last quarter. Vanguard Group Inc. boosted its holdings in CRISPR Therapeutics by 2.9% during the first quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after buying an additional 46,148 shares in the last quarter. SR One Capital Management LP acquired a new stake in CRISPR Therapeutics during the first quarter valued at $71,496,000. Dimensional Fund Advisors LP grew its position in CRISPR Therapeutics by 2.1% during the second quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock valued at $51,326,000 after buying an additional 19,094 shares during the period. Finally, Farallon Capital Management LLC purchased a new position in CRISPR Therapeutics in the second quarter valued at $28,625,000. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $45.37 on Friday. The stock’s 50 day simple moving average is $48.17 and its 200-day simple moving average is $54.95. The stock has a market cap of $3.85 billion, a P/E ratio of -16.68 and a beta of 1.68. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. During the same quarter in the prior year, the business earned ($0.98) earnings per share. The business’s revenue was down 99.3% compared to the same quarter last year. As a group, research analysts expect that CRISPR Therapeutics AG will post -5.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CRSP shares. Rodman & Renshaw assumed coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They set a “buy” rating and a $90.00 target price on the stock. Piper Sandler reissued an “overweight” rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a report on Monday, June 17th. Truist Financial cut their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Finally, StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Friday, August 16th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $75.19.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.